+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Myelodysplastic Syndrome Market - Global Forecast 2025-2030- Product Image
Myelodysplastic Syndrome Market - Global Forecast 2025-2030- Product Image
Sale

Myelodysplastic Syndrome Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968770
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Myelodysplastic Syndrome market presents a rapidly evolving environment shaped by therapeutic innovation, changing patient needs, and regional differences in care delivery. Senior executives require targeted, actionable insight to inform portfolio strategies and operational responses to dynamic global trends.

Market Snapshot: Myelodysplastic Syndrome Market Growth and Dynamics

The Myelodysplastic Syndrome Market grew from USD 2.84 billion in 2024 to USD 3.14 billion in 2025. It is expected to continue growing at a CAGR of 10.10%, reaching USD 5.07 billion by 2030. A combination of clinical advances, shifting regulatory requirements, and cross-regional procurement strategies is accelerating market expansion. Public and private sector investment in next-generation therapies is fueling demand, with stakeholders prioritizing effective treatment access and sustainable cost management. The integration of personalized medicine, digital monitoring, and adaptive trial design is further shaping both commercial and clinical success.

Scope & Segmentation: Comprehensive Market Coverage

This report provides a strategic breakdown of the Myelodysplastic Syndrome market, detailing critical segments, regions, and emerging technologies.

  • Product Types: Branded, Generic
  • Therapy Lines: First Line, Second Line, Third Line
  • End Users: Hospitals, Specialty Clinics, Home Healthcare
  • Treatment Types: Chemotherapy Agents (Cytarabine, Daunorubicin), Hypomethylating Agents (Azacitidine, Decitabine, Guadecitabine), Immunomodulators (Lenalidomide, Pomalidomide, Thalidomide), Supportive Care (Blood Transfusions, Growth Factors), Targeted Therapies (IDH Inhibitors—Enasidenib, Ivosidenib, Luspatercept, Venetoclax)
  • Distribution Channels: Offline, Online
  • Regional Coverage: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (UK, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Company Landscape: Bristol-Myers Squibb Company, Otsuka Pharmaceutical Co., Novartis International AG, Roche Holding AG, Johnson & Johnson, Pfizer Inc., AbbVie Inc., Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Amgen Inc.

Key Takeaways for Senior Decision-Makers

  • Precision medicine and patient stratification are leading to better-targeted treatment protocols and improved clinical outcomes.
  • Collaboration among pharmaceutical developers, diagnostics, and providers enhances the speed and impact of therapy development and approval.
  • Digital health platforms and telemedicine are expanding real-time monitoring, supporting both adherence and data-driven care decisions.
  • Payer partnerships and risk-sharing agreements are helping align pricing models with patient access goals and value creation.
  • Strategic alliances—including regional manufacturing and biosimilar development—are introducing cost-competitive options and broadening access channels.
  • Evolving end user demands from hospitals to home healthcare require responsive supply chains and flexible service models.

Tariff Impact: Supply Chain and Cost Pressures

Recent United States tariff changes have affected the import and distribution of critical therapeutics for Myelodysplastic Syndrome. Increased duties on pharmaceutical components are raising cost pressures across the value chain. Manufacturers and distributors are reevaluating sourcing agreements and logistics to mitigate these impacts. The dynamic nature of compliance requirements has caused intermittent supply delays. Nearshoring, revised contracts, and advocacy with regulatory bodies are underway to maintain uninterrupted patient access and sustain market stability.

Methodology & Data Sources

This report is built on a mixed-methods research framework. It combines primary interviews with oncologists, pharmacists, payers, and patient representatives, and synthesizes secondary sources such as peer-reviewed studies, regulatory filings, and health economics analysis. Quantitative modeling incorporates real-world treatment utilization and supply chain metrics, ensuring robust scenario analysis and data triangulation. Multiple expert reviews validate the findings presented.

Why This Report Matters: Outcomes for Leadership Teams

  • It empowers strategic planning with a thorough understanding of key market drivers, emerging therapeutic trends, and regional nuances.
  • It equips decision-makers to anticipate and respond proactively to regulatory, supply chain, and access challenges in the Myelodysplastic Syndrome landscape.
  • It supports risk mitigation and portfolio optimization based on actionable segmentation, competitor positioning, and cross-border dynamics insights.

Conclusion

Senior leadership will benefit from this report’s clear synthesis of evolving market trends, segmentation, and strategic opportunities. Action-oriented insights support effective resource allocation and expansion of patient-centered solutions in Myelodysplastic Syndrome care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in targeted hypomethylating agents driving improved treatment outcomes in high-risk MDS patients
5.2. Emergence of novel gene-editing therapies aiming to correct underlying hematopoietic stem cell mutations in MDS
5.3. Growing adoption of next-generation sequencing for personalized prognosis and risk stratification in MDS management
5.4. Increasing focus on combination therapies integrating immunomodulators with standard MDS treatment regimens
5.5. Expansion of outpatient transfusion and supportive care services enhancing quality of life for MDS patients
5.6. Development of oral formulations of hypomethylating agents to improve patient adherence in MDS therapy
5.7. Rise of real-world evidence studies assessing long-term outcomes of emerging MDS therapies across diverse populations
5.8. Increased investment in biomarker-driven clinical trials to identify predictive markers of response in MDS
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Myelodysplastic Syndrome Market, by Product Type
8.1. Introduction
8.2. Branded
8.3. Generic
9. Myelodysplastic Syndrome Market, by Therapy Line
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line
10. Myelodysplastic Syndrome Market, by End User
10.1. Introduction
10.2. Home Healthcare
10.3. Hospitals
10.4. Specialty Clinics
11. Myelodysplastic Syndrome Market, by Treatment Type
11.1. Introduction
11.2. Chemotherapy Agents
11.2.1. Cytarabine
11.2.2. Daunorubicin
11.3. Hypomethylating Agents
11.3.1. Azacitidine
11.3.2. Decitabine
11.3.3. Guadecitabine
11.4. Immunomodulators
11.4.1. Lenalidomide
11.4.2. Pomalidomide
11.4.3. Thalidomide
11.5. Supportive Care
11.5.1. Blood Transfusions
11.5.2. Growth Factors
11.6. Targeted Therapies
11.6.1. IDH Inhibitors
11.6.1.1. Enasidenib
11.6.1.2. Ivosidenib
11.6.2. Luspatercept
11.6.3. Venetoclax
12. Myelodysplastic Syndrome Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.3. Online
13. Americas Myelodysplastic Syndrome Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Myelodysplastic Syndrome Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Myelodysplastic Syndrome Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Bristol-Myers Squibb Company
16.3.2. Otsuka Pharmaceutical Co., Ltd.
16.3.3. Novartis International AG
16.3.4. Roche Holding AG
16.3.5. Johnson & Johnson
16.3.6. Pfizer Inc.
16.3.7. AbbVie Inc.
16.3.8. Astellas Pharma Inc.
16.3.9. Takeda Pharmaceutical Company Limited
16.3.10. Amgen Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. MYELODYSPLASTIC SYNDROME MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. MYELODYSPLASTIC SYNDROME MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. MYELODYSPLASTIC SYNDROME MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. MYELODYSPLASTIC SYNDROME MARKET: RESEARCHAI
FIGURE 26. MYELODYSPLASTIC SYNDROME MARKET: RESEARCHSTATISTICS
FIGURE 27. MYELODYSPLASTIC SYNDROME MARKET: RESEARCHCONTACTS
FIGURE 28. MYELODYSPLASTIC SYNDROME MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MYELODYSPLASTIC SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CYTARABINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CYTARABINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DAUNORUBICIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DAUNORUBICIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY AZACITIDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY AZACITIDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DECITABINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DECITABINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY GUADECITABINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY GUADECITABINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THALIDOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY BLOOD TRANSFUSIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY BLOOD TRANSFUSIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ENASIDENIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ENASIDENIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IVOSIDENIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IVOSIDENIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY LUSPATERCEPT, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY LUSPATERCEPT, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY VENETOCLAX, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY VENETOCLAX, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 139. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 140. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 141. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 142. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 143. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 146. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 147. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 148. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 149. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 150. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 151. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 152. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 153. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 154. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 155. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 156. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 157. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 158. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 159. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 162. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 163. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 164. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 165. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 168. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 169. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 170. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 171. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 172. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 173. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 174. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 175. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 176. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 177. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 178. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 179. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 180. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 181. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 274. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 275. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 276. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 277. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 280. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 281. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 282. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 283. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 284. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 285. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 286. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 287. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 288. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 289. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 290. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 291. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 292. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 293. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 296. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 297. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 298. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 299. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 302. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 303. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 304. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 305. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 306. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 307. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 308. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 309. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 310. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 311. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 312. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 313. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 314. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 315. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION

Samples

Loading
LOADING...

Companies Mentioned

  • Bristol-Myers Squibb Company
  • Otsuka Pharmaceutical Co., Ltd.
  • Novartis International AG
  • Roche Holding AG
  • Johnson & Johnson
  • Pfizer Inc.
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.14 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.07 Billion
Compound Annual Growth Rate10.1%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Myelodysplastic Syndrome Drug Market - Global Forecast 2025-2030 - Product Image

Myelodysplastic Syndrome Drug Market - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Myelodysplastic Syndrome Drug Pipeline Analysis Report 2025 - Product Image

Myelodysplastic Syndrome Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Myelodysplastic Syndrome Market Report 2025 - Product Image

Myelodysplastic Syndrome Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Myelodysplastic Syndrome - Global Clinical Trials Review, 2025 - Product Image

Myelodysplastic Syndrome - Global Clinical Trials Review, 2025

  • Clinical Trials
  • 2143 Pages
  • Global
From
Myelodysplastic Syndrome: Competitive Landscape - Product Image

Myelodysplastic Syndrome: Competitive Landscape

  • Report
  • 84 Pages
  • Global
From

About the Myelodysplastic Syndrome Drugs Market

Myelodysplastic Syndrome (MDS) is a type of cancer that affects the bone marrow and blood cells. It is a rare disorder that can lead to anemia, infections, and bleeding. Treatment for MDS includes chemotherapy, radiation therapy, and stem cell transplantation. Drugs used to treat MDS include hypomethylating agents, such as azacitidine and decitabine, and immunomodulatory agents, such as lenalidomide and pomalidomide. These drugs are used to reduce the risk of disease progression and improve the quality of life for patients. The Myelodysplastic Syndrome Drugs market is a part of the larger Oncology Drugs market. It is a rapidly growing market, driven by the increasing prevalence of MDS and the development of new drugs. The market is expected to continue to grow in the coming years, as new drugs are developed and approved for use. Some of the major companies in the Myelodysplastic Syndrome Drugs market include Celgene Corporation, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Merck & Co. Inc. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.